If you have been reading about Certificate of analysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
=== Non-human infection === Treponema pallidum has been found in non-human primates in multiple different geographical regions. In Tanzania specifically, T. pallidum geographical distribution closely aligns with the distribution of yaws in humans. The most common strains in NHPs are T. p. pertenue and T. p.endemicum. It is unclear however whether or not these NHP strains can naturally infect humans, but flies have been proposed as possible vectors in an alternative transmission route. Clinically, these infections range from asymptomatic to severe skin ulceration that affect the face or genitalia in these primates. Infection of NHPs is largely reliant on ecological patterns, behaviors, and interactions between the species. There are no current treatments available for infected NHPs.
=== Aerosol and particulate matter inlet === Researchers at the Leopold-Franzens University in Innsbruck invented a dedicated PTR-MS inlet system for the analysis of aerosols and particulate matter, which they called "CHemical Analysis of aeRosol ON-line (CHARON)". After further development work in collaboration with a PTR-MS manufacturer, CHARON has become readily available as an add-on for PTR-MS instruments in 2017. The add-on consists of a honeycomb activated charcoal denuder which adsorbs organic gases but transmits particles, an aerodynamic lens system that collimates sub-μm particles, and a thermo-desorber that evaporates non-refractory organic particulate matter at moderate temperatures of 100-160 °C and reduced pressures of a few mbar. So far, CHARON has predominantly been used within studies in the field of atmospheric chemistry, e.g. for airborne measurements of particulate organic matter and bulk organic aerosol analysis.
=== Hepatitis C === Ritonavir is also utilized as a pharmacokinetic booster in direct-acting antiviral regimens for the treatment of Hepatitis C (HCV). It is formulated in combination with paritaprevir and ombitasvir (and sometimes dasabuvir), where ritonavir boosts the systemic levels of paritaprevir to maintain effective antiviral concentrations, achieving high sustained virological response rates with a manageable safety profile.
Sources: en.wikipedia.org
Somorjai (born 1935), 1998 Wolf Prize in Chemistry Georg Ernst Stahl (1659–1734), Important work on fermentation Wendell Meredith Stanley (1904–1971), 1946 Nobel Prize in Chemistry Jean Servais Stas (1813–1891), Belgian analytical chemist Branko Stanovnik (born 1938), chemist Hermann Staudinger (1881–1965), polymer chemist, 1953 Nobel Prize in Chemistry Harry Steenbock (1886–1967), American biochemist, worked on ultraviolet irradiation William Howard Stein (1911–1980), 1972 Nobel Prize in Chemistry Thomas A. Steitz (1940–2018), 2009 Nobel Prize in Chemistry Douglas Stephan, Frustrated Lewis Pairs Rose Stern (1869–1953), first British woman member of the Royal Institute of Chemistry Alfred Stock (1876–1946), German inorganic chemist, known for work in mercury poisoning Brian Stoltz (born 1970), award-winning American organic chemist. Fraser Stoddart (1942–2024), Scottish chemist, a pioneer in the field of the mechanical bond Molly Shoichet, award-winning Canadian biomedical engineer known for her work in tissue engineering. She is the only person to be a fellow of the three National Academies in Canada F. Gordon A. Stone (1925–2011), British inorganic chemist S. Donald Stookey (1915–2014), American glass and ceramic chemist Gilbert Stork (1921–2017), 1995/6 Wolf Prize in Chemistry Friedrich August Kekulé von Stradonitz (1829–1896), German organic chemist, principal founder of chemical structure Yellapragada Subbarow (1895-1948), Indian biochemist known for discovery of ATP and synthesis of many new ground breaking compounds James B.
=== Wrongful death lawsuits === Carrey's girlfriend Cathriona White married Mark Burton in 2013, in Las Vegas. She and Carrey had been dating on and off since 2012, and she was still married but dating Carrey when she died in 2015. On September 19, 2016, Burton filed a wrongful death lawsuit against Carrey, claiming that he had used his "immense wealth and celebrity status" to illegally obtain and distribute prescription drugs involved in White's death. Carrey released a statement the following day:
Pseudoephedrine is available by itself over-the-counter in the form of 30 and 60 mg immediate-release and 120 and 240 mg extended-release oral tablets in the United States. Pseudoephedrine is also available over-the-counter and prescription-only in combination with numerous other drugs, including antihistamines (acrivastine, azatadine, brompheniramine, cetirizine, chlorpheniramine, clemastine, desloratadine, dexbrompheniramine, diphenhydramine, fexofenadine, loratadine, triprolidine), analgesics (acetaminophen, codeine, hydrocodone, ibuprofen, naproxen), cough suppressants (dextromethorphan), and expectorants (guaifenesin). Pseudoephedrine has been used in the form of the hydrochloride and sulfate salts and in a polistirex form. The drug has been used in more than 135 over-the-counter and prescription formulations. Many prescription formulations containing pseudoephedrine have been discontinued over time.
Sources: en.wikipedia.org
Such trials in the communist regime were quite common and a typical practice of suppressing the right to free speech. Bosnian politicians used this practice to reaffirm their political opposition to Serbian nationalist tendencies and in particular opposition to the politics of Slobodan Milošević who was trying to revert the constitutional amendments of the 1970s that awarded the Bosniaks the status of a constituent ethnicity. The process also backfired as the Serbian lobby insisted that Bosnia was a "dark nation" where all those who oppose the government will be prosecuted, where Bosnian Muslim communists were prosecuting Muslim believers. That kind of propaganda attracted many Bosnian Muslims to their way of thinking. Others were interpreting the Sarajevo process as a way of removing the political amateurs who could end up disrupting the process of Bosnian independence.
Examples include alpha-Amanitin containing mushrooms, kava, and aflatoxin producing molds. Pyrrolizidine alkaloids, which occur in some plants, can be toxic. Green tea extract is a growing cause of liver failure due to its inclusion in more products.
The knockout stage used a single-elimination format, starting with the newly introduced round of 32 on June 28 and culminating with the final on July 19, with a match for third place the day before. If the score was even after regulation time in a match, 30 minutes of extra time were added. If still tied after this, a penalty shootout determined the winner.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.